Aerie Pharms Inc Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for AERIE PHARMS INC, and what generic alternatives to AERIE PHARMS INC drugs are available?
AERIE PHARMS INC has two approved drugs.
There are fifteen US patents protecting AERIE PHARMS INC drugs.
There are fifty-nine patent family members on AERIE PHARMS INC drugs in nine countries and fourteen supplementary protection certificates in seven countries.
Summary for Aerie Pharms Inc
International Patents: | 59 |
US Patents: | 15 |
Tradenames: | 2 |
Ingredients: | 2 |
NDAs: | 2 |
Drugs and US Patents for Aerie Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 11,197,853 | See Plans and Pricing | Y | See Plans and Pricing | |||
Aerie Pharms Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | 9,415,043 | See Plans and Pricing | Y | See Plans and Pricing | |||
Aerie Pharms Inc | ROCKLATAN | latanoprost; netarsudil dimesylate | SOLUTION/DROPS;OPHTHALMIC | 208259-001 | Mar 12, 2019 | RX | Yes | Yes | 10,654,844 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Aerie Pharms Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | 9,931,336 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Aerie Pharms Inc | RHOPRESSA | netarsudil mesylate | SOLUTION/DROPS;OPHTHALMIC | 208254-001 | Dec 18, 2017 | RX | Yes | Yes | 9,096,569 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Aerie Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Hong Kong | 1225733 | See Plans and Pricing |
Japan | 2019142953 | See Plans and Pricing |
Canada | 2760611 | See Plans and Pricing |
Australia | 2009273932 | See Plans and Pricing |
Spain | 2553827 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Aerie Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3461484 | 122021000036 | Germany | See Plans and Pricing | PRODUCT NAME: LATANOPROST, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND NETARSUDIL MESYLAT; REGISTRATION NO/DATE: EU/1/20/1502 20210107 |
3053913 | 2020/016 | Ireland | See Plans and Pricing | PRODUCT NAME: NETARSUDIL, OR AN ENANTIOMER, DIASTEREOMER, SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
3053913 | 301038 | Netherlands | See Plans and Pricing | PRODUCT NAME: NETARSUDIL, OF EEN ZOUT OF SOLVAAAT DAARVAN, IN HET BIJZONDER NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/19/1400 20191121 |
3053913 | 2020C/510 | Belgium | See Plans and Pricing | PRODUCT NAME: RHOKIINSA - NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/19/1400 20191121 |
3461484 | C202130024 | Spain | See Plans and Pricing | PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.